Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
GV20 Therapeutics›
Website
AddedFeb 15, 2024
UpdatedJun 18, 2026
GV20 Therapeutics

GV20 Therapeutics

Series B

GV20 Therapeutics, a US-based firm, uses AI and genomics to discover and develop novel cancer immunology drugs.

HQ
Cambridge, MA, US
Founded
2016
Loading
Overview
Compare
Fundraising
Employees
Website

GV20 Therapeutics - Website

An index of every page on gv20tx.com, by section.

11 pages across 6 sections · Updated Jul 16, 2026·

Homepage

GV20 Therapeutics's front door: current positioning and top-line messaging.

gv20tx.com

Careers

Open roles and how GV20 Therapeutics recruits, straight from the source.

gv20tx.com/careers

BlogNews

Product updates, deep-dives, and company thinking: GV20 Therapeutics's 6-post archive.

gv20tx.com/news
  • GV20 Therapeutics Announces Late-Breaking Oral Presentation of GV20-0251 Translational Findings at the AACR Annual Meeting 2026 Mar 17, 2026Read More/news/details/20260317
  • GV20 Therapeutics Announces Achievement of Milestone under Antibody-Drug Conjugate Collaboration with Mitsubishi Tanabe Pharma Corporation Nov 25, 2025Read More/news/details/20251125
  • GV20 Therapeutics Presents Updated Phase 1 Monotherapy Data on GV20-0251 at the ASCO Annual Meeting 2025 Jun 2, 2025Read More/news/details/20250602
  • GV20 Therapeutics Presents Cancer-Extrinsic Mechanism of Action Data on GV20-0251 at the AACR Annual Meeting 2025 Apr 29, 2025Read More/news/details/20250429
  • GV20 Therapeutics Announces Collaboration Agreement with Mitsubishi Tanabe Pharma Corporation to Develop Novel Antibody-Drug Conjugates Mar 26, 2025Read More/news/details/20250326

Products / ServicesPlatform

The products and services as GV20 Therapeutics markets them.

gv20tx.com/platform

Team

Leadership and the people behind GV20 Therapeutics, as the company presents them.

gv20tx.com/team

Contact

Sales, support, and partnership channels for reaching GV20 Therapeutics directly.

gv20tx.com/contact